ADMA Biologics Inc PE Ratio 2013-2021 | ADMA

Current and historical p/e ratio for ADMA Biologics Inc (ADMA) from 2013 to 2021. The price to earnings ratio is calculated by taking the latest closing price and dividing it by the most recent earnings per share (EPS) number. The PE ratio is a simple way to assess whether a stock is over or under valued and is the most widely used valuation measure. ADMA Biologics Inc PE ratio as of October 26, 2021 is 0.00.

Please refer to the Stock Price Adjustment Guide for more information on our historical prices.

ADMA Biologics Inc PE Ratio Historical Data
Date Stock Price TTM Net EPS PE Ratio
2021-10-27 1.35 0.00
2021-06-30 1.60 $-0.70 0.00
2021-03-31 1.76 $-0.78 0.00
2020-12-31 1.95 $-0.88 0.00
2020-09-30 2.39 $-0.86 0.00
2020-06-30 2.93 $-0.86 0.00
2020-03-31 2.88 $-0.88 0.00
2019-12-31 4.00 $-0.90 0.00
2019-09-30 4.45 $-1.11 0.00
2019-06-30 3.87 $-1.25 0.00
2019-03-31 3.79 $-1.35 0.00
2018-12-31 2.39 $-1.46 0.00
2018-09-30 6.21 $-1.31 0.00
2018-06-30 4.51 $-0.39 0.00
2018-03-31 4.60 $-0.59 0.00
2017-12-31 3.21 $-0.71 0.00
2017-09-30 3.08 $-0.82 0.00
2017-06-30 3.70 $-1.75 0.00
2017-03-31 4.88 $-1.70 0.00
2016-12-31 5.12 $-1.62 0.00
2016-09-30 7.24 $-1.71 0.00
2016-06-30 5.95 $-1.85 0.00
2016-03-31 8.09 $-1.79 0.00
2015-12-31 8.07 $-1.73 0.00
2015-09-30 8.36 $-1.67 0.00
2015-06-30 9.26 $-1.55 0.00
2015-03-31 9.80 $-1.54 0.00
2014-12-31 11.17 $-1.17 0.00
2014-09-30 10.30 $-0.79 0.00
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.179B $0.042B
ADMA Biologics, Inc. is a specialty immune globulin company. It develops, manufactures and intends to market plasma-based biologics for the treatment and prevention of certain infectious diseases. The Company's target patient populations include immune-compromised individuals who suffer from an underlying immune deficiency disease or who may be immune-suppressed for medical reasons. Its lead product candidate, RI-002, which is in Phase III clinical trial, is intended for the treatment of primary immune deficiency disease. ADMA Biologics, Inc. is headquartered in Ramsey, New Jersey.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $129.416B 8.62
Bio-Rad Laboratories (BIO.B) United States $21.730B 46.31
QIAGEN (QGEN) Netherlands $12.526B 21.21
Biohaven Pharmaceutical Holding (BHVN) United States $9.249B 0.00
Emergent Biosolutions (EBS) United States $2.705B 6.53
Arcus Biosciences (RCUS) United States $2.404B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.873B 0.00
Myovant Sciences (MYOV) United Kingdom $1.831B 0.00
Zymeworks (ZYME) Canada $1.080B 0.00
Ambrx Biopharma (AMAM) United States $0.464B 0.00
SQZ Biotechnologies (SQZ) United States $0.372B 0.00
Enzo Biochem (ENZ) United States $0.161B 15.86